Max J Gordon

17PUBLICATIONS
39CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingHaematological tumoursCardiology (incl. cardiovascular diseases)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Mar 04, 2026
A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.

Max J Gordon, Milos D Miljkovic, Paige Milhon

|Jun 16, 2025
The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas.

Rahul Lakhotia, Christopher Melani, Stefania Pittaluga

|Apr 29, 2024
Comparison of Comorbidity Models Within a Population-Based Cohort of Older Adults With Non-Hodgkin Lymphoma.

Max J Gordon, Zhigang Duan, Hui Zhao

|Nov 20, 2023
Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.

Max J Gordon, Lei Feng, Paolo Strati

|Sep 14, 2023
Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma.

Max J Gordon, Zhigang Duan, Hui Zhao

|Apr 05, 2023
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.

Max J Gordon, Jade E Jones, Binsah George

Pageof 3

Frequent Collaborators

3 joint publications

Christopher Melani

2 joint publications

Rahul Lakhotia

2 joint publications

Mark Roschewski

2 joint publications

Stefania Pittaluga